Status:
RECRUITING
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Cancer-associated Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of rec...
Detailed Description
CAN-CATCH study is a prospective cohort study to develop a risk assessment model for VTE recurrence and clinically relevant bleeding in patients with CAT. The study is anticipated to recruit for a per...
Eligibility Criteria
Inclusion
- Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
- Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.
- Estimated life expectancy \> 6 months
- Willingness to give an informed consent
- Age ≥ 18 years
Exclusion
- Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
- Superficial vein thrombosis
- Refusal of informed consent \> 72 hrs of anticoagulants
- Age \< 18 years old
Key Trial Info
Start Date :
December 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06894576
Start Date
December 3 2024
End Date
December 1 2027
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H8L6